Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|AAML0121||COG||"A Phase II Study of Amifostine In Children with Myelodysplastic Syndrome: A Group-wide Study"||Pediatric CIRB||Completed|
|ACNS1833||COG||A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)||Pediatric CIRB||Available to Open|
|ASCT1221||COG||A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML)||Pediatric CIRB||Completed|
|ANBL0931||COG||A Comprehensive Safety Trial of Chimeric Antibody 14.18 (ch14.18) with GM-CSF; IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: A Limited Institution Study||Pediatric CIRB||Available to Open|
|AOST1321||COG||Phase II Study of Denosumab (IND #127430; NSC# 744010); a RANK Ligand Antibody; for Recurrent or Refractory Osteosarcoma||Pediatric CIRB||Available to Open|
|AEWS1221||COG||Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479; NSC# 750008; IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma||Pediatric CIRB||Available to Open|
|ACCL10P1||COG||Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study||Pediatric CIRB||Available to Open|
|ARST0332||COG||Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|ADVL18P1||COG||An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) with an Isocitrate Dehydrogenase-2 (IDH2) Mutation||Pediatric CIRB||Available to Open|
|ACNS1022||COG||A Phase II Randomized Trial of Lenalidomide (NSC # 703813; IND # 70116) in Pediatric Patients with Recurrent; Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas: A Groupwide Phase II Study||Pediatric CIRB||Available to Open|